Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 11, 2014, Pages 1801-1809

  Arachchillage, D R J ^a   Efthymiou, M ^a   Mackie, I J ^a   Lawrie, A S ^a   Machin, S J ^a   Cohen, H ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Activated protein C resistance; Antibodies; Antiphospholipid syndrome; Protac; Protein C; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; PEPTIDE; PHOSPHOLIPID ANTIBODY; PROTEIN C; RECOMBINANT PROTEIN; SNAKE VENOM PROTEIN C ACTIVATOR; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PHENOTYPE; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PHENOTYPE; PROTEIN C; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84920269499     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12722     Document Type: Article

References (37)

1. Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11(Suppl. 1): 242-53.
2. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
3. Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-66.
4. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
5. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, David M, Andrew ME. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 844-9.
6. Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005; 51: 545-52.
7. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Thromb Haemost 2002; 88: 716-22.
8. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-4.
9. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-7.
10. Keeling DM, Wilson AJ, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46: 908-11.
11. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-55.
12. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 2008; 54: 2042-8.
13. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
14. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
15. Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-7.
16. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
17. Tripodi A. The history of phenotypic testing in thrombosis and hemostasis. Semin Thromb Hemost 2008; 34: 585-92.
18. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6: 1720-5.
19. Arachchillage J, Efthymiou M, Mackie I, Lawrie A, Machin S, Cohen H. Investigation of resistance to exogenous activated protein C and activation of endogenous protein C in thrombotic patients with or without antiphospholipid syndrome. J Thromb Haemost 2013; 11: 335-6.
20. Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping the haemostatic system by thrombography - potential for the estimation of thrombotic risk. Thromb Res 2004; 114: 539-45.
21. Wahl D, Regnault V, Beguin S, de Maistre E, Kaminsky P, Hemker HC, Lecompte T. Thrombography allows reliable study of the protein C system in APS and evidences a strong phenotypic heterogeneity. Thromb Res 2004; 114: 1639-40.
22. Liestol S, Sandset PM, Jacobsen EM, Mowinckel MC, Wisloff F. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Br J Haematol 2007; 136: 131-7.
23. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
24. Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007; 5: 2204-10.
25. Zuily S, Regnault V, Guillemin F, Kaminsky P, Rat AC, Lecompte T, Wahl D. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013; 132: e1-7.
26. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
27. Kasthuri RS, Roubey RA. Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum 2007; 57: 1346-7.
28. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-95.
29. Martinoli JL, Stocker K. Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 1986; 43: 253-64.
30. Green L, Safa O, Machin SJ, Mackie IJ, Ryland K, Cohen H, Lawrie AS. Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway. Thromb Res 2012; 130: 780-4.
31. Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8: 1994-2000.
32. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004; 63: 1478-82.
33. Devreese K, Peerlinck K, Arnout J, Hoylaerts MF. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 2009; 101: 185-96.
34. Oosting JD, Derksen RH, Hackeng TM, van Vliet M, Preissner KT, Bouma BN, de Groot PG. In vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66: 666-71.
35. Borrell M, Sala N, de CC, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-72.
36. Lambrianides A, Turner-Stokes T, Pericleous C, Ehsanullah J, Papadimitraki E, Poulton K, Ioannou Y, Lawrie A, Mackie I, Chen P, Latchman D, Isenberg D, Rahman A, Giles I. Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. Arthritis Rheum 2011; 63: 3512-21.
37. Bertolaccini ML, Sanna G, Ralhan S, Gennari LC, Merrill JT, Khamashta MA, Hughes GR. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 2003; 90: 636-41.